The program increased hypertension management rates to 77% in 2017.
Patients taking PPIs 28.4 times more likely to develop chronic kidney disease.
Researchers targeting virus' receptors used to enter the body.
First drug approved for PPD use to remain under REMS program.
Study finds different anticoagulation treatment levels for patients with cognitive problems.
Safety monitoring findings for Shingrix are consistent with clinical trial data.
Pregnancy and menopause are contributing factors.
Scott Gottlieb’s tenure at the FDA was marked by hundreds of generic approvals and aggressive moves against the tobacco industry and vaping.
Updated recommendations for the diagnosis, treatment, prevention, and outbreak management of seasonal influenza.
Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.